Argenx Se AI Stock Analysis
Want to see ARGX full AI Analyst Report?
Argenx Se (ARGX) AI Stock Analysis
Argenx Se
(NASDAQ:ARGX)
Overall score reflects standout fundamentals (rapid growth, strong margins, and an exceptionally low-leverage balance sheet) as the primary positive driver, reinforced by a bullish earnings-call outlook with multiple potential 2027 launch catalysts. The score is tempered by mixed/soft technical momentum and execution risk from sharply higher planned operating expenses alongside some pipeline setbacks and uneven historical cash-flow consistency.
Argenx Se Key Performance Indicators (KPIs)
Revenue By SegmentBreaks down revenue by business segment, offering insight into which areas are driving growth, profitability, and strategic focus.
Product revenue has become the dominant, high‑velocity driver—growing into multi‑billion quarters and absorbing the decline of collaboration receipts—while "Other" is steadily rising, suggesting expanding ancillary revenue or milestone/market openings. The mid‑2025 spike and subsequent dip look like timing/channel or milestone recognition rather than demand loss; management’s latest call (record product sales, broad prescriber adoption and label expansion) reinforces sustainable commercial momentum, but watch rising operating spend and payer/habit barriers that could slow longer‑term penetration.
Argenx Se (ARGX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $60.03B
- Dividend Yield
- ―
- Average Volume (3M)
- 366.80K
- Price to Earnings (P/E)
- 45.5
- Beta (1Y)
- 0.31
- Revenue Growth
- 70.57%
- EPS Growth
- 30.28%
- Country
- US
- Employees
- 1,863
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Argenx Se Business Overview & Revenue Model
Company Description
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United St...
How the Company Makes Money
argenx primarily makes money by commercializing its prescription biologic medicines, generating revenue from product sales to healthcare providers and distributors in the regions where its therapies are approved and reimbursed. A major revenue stream...
Argenx Se Earnings Call Summary
The call was strongly positive, supported by 54% year-over-year product sales growth, continued momentum in both MG and CIDP, positive ALKIVIA and FB102 data, a broadening pipeline and expectations for up to five potential launches in 2027. The main challenges were the dermatomyositis confirmatory-trial requirement, the Sjögren's futility outcome, elevated planned operating expenses and limited formal revenue guidance, but these issues were outweighed by the company's commercial performance, financial strength and pipeline progress.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects 10 molecules in clinical development by the end of this year, combined R&D and SG&A expenses of approximately $4 billion for 2026, a 45% increase year-over-year from 2025, and for 2027 said, “please do not assume another 45% increase,” with investors to “Think of about half of that 45% if you need something for your models now”; more guidance is expected at JPMorgan. The company expects 5 potential launches across its portfolio in 2027, or “up to 5 launches in a single year in the U.S.,” including a pediatric MG PDUFA date of February 2027, a VYVGART Hytrulo auto-injector in the second half of 2027, an IMNM sBLA by year-end, and potentially MMN following the EMPASSION readout in December and a priority-review application if data are positive. Management expects about 2 quarters after approval to get payer policies in place for IMNM, expects 10 clinical-stage molecules by the end of this year, is “well on track” for 10 labeled indications and 5 molecules in Phase III development by the end of the decade, and reiterated Vision 2030 targets of 50,000 patients by the end of the decade.
Argenx Se Financial Statement Overview
Summary
Strong financial profile led by a sharp profitability inflection and rapid revenue acceleration (2025 revenue +81.5% YoY) with very high margins (gross ~89%, operating ~23%, net ~31%). Balance sheet strength is exceptional with minimal leverage (debt-to-equity ~0.01) and growing equity base, supporting continued R&D and commercialization. Main constraint is durability/quality of cash generation: cash flows were negative in 2021–2024 and 2025 cash conversion (operating cash flow vs. net income) is not yet consistently strong.
Income Statement
86Very PositiveBalance Sheet
95Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.02B | 4.15B | 2.19B | 1.23B | 410.75M | 1.08B |
| Gross Profit | 5.40B | 3.70B | 1.96B | 1.11B | 381.31M | 497.28M |
| EBITDA | 1.87B | 1.31B | 105.17M | -192.28M | -622.78M | -392.78M |
| Net Income | 1.89B | 1.29B | 833.04M | -295.05M | -709.59M | -408.26M |
Balance Sheet | ||||||
| Total Assets | 10.03B | 8.68B | 6.20B | 4.54B | 3.13B | 2.85B |
| Cash, Cash Equivalents and Short-Term Investments | 5.18B | 4.44B | 3.38B | 3.18B | 2.19B | 2.34B |
| Total Debt | 47.00M | 83.49M | 39.05M | 20.00M | 12.43M | 11.46M |
| Total Liabilities | 1.61B | 1.36B | 704.24M | 444.95M | 320.56M | 316.05M |
| Stockholders Equity | 8.42B | 7.32B | 5.50B | 4.10B | 2.81B | 2.53B |
Cash Flow | ||||||
| Free Cash Flow | 1.16B | 844.30M | -151.05M | -464.14M | -966.63M | -728.25M |
| Operating Cash Flow | 1.16B | 850.49M | -82.75M | -420.33M | -862.81M | -606.81M |
| Investing Cash Flow | 70.75M | 823.88M | -717.59M | 308.21M | -461.18M | -347.07M |
| Financing Cash Flow | 262.43M | 233.73M | 279.76M | 1.34B | 843.76M | 1.12B |
Argenx Se Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARGX, the sentiment is Positive. The current price of 950.95 is above the 20-day moving average (MA) of 907.57, above the 50-day MA of 923.88, and above the 200-day MA of 860.28, indicating a bullish trend. The MACD of 18.56 indicates Negative momentum. The RSI at 58.77 is Neutral, neither overbought nor oversold. The STOCH value of 88.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARGX.
Argenx Se Risk Analysis
Argenx Se disclosed 60 risk factors in its most recent earnings report. Argenx Se reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskArgenx Se Peers Comparison
Overall Rating
REGN81Outperform
ARGX76Outperform
GMAB63Neutral
XNCR61Neutral
IMVT53Neutral
ZYME48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $98.82B | 20.35 | 15.07% | 0.39% | 18.59% | 8.14% | |
| 76Outperform | $60.89B | 45.50 | 16.86% | ― | 70.57% | 30.28% | |
| 63Neutral | $30.47B | 42.80 | 12.26% | ― | 19.61% | -50.40% | |
| 61Neutral | $2.78B | -23.62 | -21.29% | ― | 33.55% | 11.51% | |
| 53Neutral | $7.07B | -13.35 | -63.01% | ― | ― | 9.82% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $1.83B | 39.16 | 22.48% | ― | 97.78% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARGX | Argenx | 950.95 | 32.42 | 3.53% | |
| REGN | Regeneron Pharmaceuticals | 952.40 | 230.76 | 31.98% | |
| XNCR | Xencor Inc. | 35.40 | 19.38 | 120.97% | |
| ZYME | Zymeworks | 26.45 | 3.46 | 15.05% | |
| GMAB | Genmab (Otc) | 51.57 | 21.25 | 70.09% | |
| IMVT | Immunovant, Inc. | 33.28 | 9.59 | 40.48% |
Argenx Se Corporate Events
Argenx Unveils New VYVGART and Pipeline Data at AANEM and MGFA
On September 29, 2026, Argenx reported new clinical and real‑world data for VYVGART in myasthenia gravis and CIDP, presented at the AANEM and MGFA meetings in Orlando. The results show deeper improvement in ocular MG with additional treatment cycles,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026
